The AEN Knockout HEK293T Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population with targeted disruption of the AEN gene. This heterogeneous pool carries diverse indel mutations that collectively ablate AEN function, providing a robust loss-of-function model for studying p53-dependent apoptosis. The polyclonal format preserves genetic diversity and avoids biases of clonal expansion, making it suitable for experiments where population-level responses are desired.
The parental HEK293T cell line is a human embryonic kidney epithelial derivative expressing SV40 large T antigen, which enhances episomal replication and protein expression. These cells are widely employed for heterologous protein production, viral vector packaging, and cell signaling research due to their high transfection efficiency and rapid growth. Their intact apoptotic machinery, including functional p53, makes them an appropriate host for investigating programmed cell death pathways.
AEN encodes an apoptosis-enhancing nuclease that promotes DNA fragmentation during programmed cell death. Induction by the transcription factor TP53 occurs in response to genotoxic stress or DNA damage. AEN acts downstream of p53 and cytochrome c release, contributing to chromatin cleavage alongside effector caspases-3 and -7. Although its direct binding partners are uncharacterized, AEN is a key mediator linking p53 signaling to nuclear DNA degradation during intrinsic apoptosis, facilitating cellular elimination in damaged or transformed cells.
In HEK293T cells with functional p53, AEN knockout allows precise dissection of the DNA fragmentation step in apoptosis. Researchers can expose the polyclonal knockout population to DNA-damaging agents like etoposide and monitor impaired chromatin cleavage via TUNEL assays, while using flow cytometry to quantify apoptosis levels. This model circumvents non-specific nuclease inhibitors, providing a clean genetic system to assess AEN??s contribution separate from caspase activities. It is particularly valuable for studying how p53-mediated cell fate decisions are executed through downstream nucleases.
Applications span investigating p53-mediated apoptosis, cancer therapy development targeting DNA damage responses, and neurodegenerative disorder research. Common assays include RT-qPCR and western blotting to validate AEN disruption, TUNEL for DNA fragmentation, annexin V/PI flow cytometry for apoptosis, immunofluorescence for caspase activation, and p53 reporter assays. The AEN Knockout HEK293T Polyclonal Cells enable comprehensive dissection of p53?CAEN signaling. For more information, contact Ascent Research.
